Gilead - Life Cycle Management For Hiv And Hcv Pipeline = Upside
MATURE BIOTECH
Subject: GILEAD – Life Cycle Management for HIV and HCV Pipeline = Upside
Abstract
3Q12 earnings (Table 1) and revised upward revenue guidance validates Gilead’s (GILD) dominance in the HIV space. With the successful launch of Complera/Eviplera (truvada+edurant, 3Q12 net sales of $99m), Stribild (L in US, R in EU, truvada+ cobicistat+elvitegravir) and expected approval of Elvitebravir (R, Integrase inhibitor, 1H13), GILD is set to lead the HIV arena beyond 2018. In the next three years, GILD should be able to repeat the feat in HCV too! For more detail, please read our report released on 1st Nov., 2012, titled, “Life Cycle Management for HIV and HCV Pipeline = Upside”.
Report type – Deep Dive
Subject: GILEAD – Life Cycle Management for HIV and HCV Pipeline = Upside
Abstract
3Q12 earnings (Table 1) and revised upward revenue guidance validates Gilead’s (GILD) dominance in the HIV space. With the successful launch of Complera/Eviplera (truvada+edurant, 3Q12 net sales of $99m), Stribild (L in US, R in EU, truvada+ cobicistat+elvitegravir) and expected approval of Elvitebravir (R, Integrase inhibitor, 1H13), GILD is set to lead the HIV arena beyond 2018. In the next three years, GILD should be able to repeat the feat in HCV too! For more detail, please read our report released on 1st Nov., 2012, titled, “Life Cycle Management for HIV and HCV Pipeline = Upside”.
Report type – Deep Dive
More Publications
Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!
US$ 90.00
March 2012
4 pages
Onyx Pharma - ASCO ’12: Kyprolis’ Data enough to obtain an ‘Accelerate Approval’?
US$ 90.00
May 2012
4 pages
MERCK - Vorapaxar shows minor Overall Net Clinical benefit- Limited commercial potential
US$ 90.00
March 2012
1 pages
Alexion - Innovative Drugs For Orphan Diseases Focus = Stability!
US$ 140.00
October 2012
5 pages
Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement
US$ 90.00
November 2011
6 pages
